What is the cost of Stelara?
The cost of Stelara (ustekinumab) can vary significantly depending on factors such as insurance coverage, pharmacy, and dosage. For individuals without insurance, a single vial of Stelara can cost several thousand dollars. For example, a 45 mg vial might range from $7,000 to over $10,000.
How can I get financial assistance for Stelara?
Patients may be eligible for financial assistance programs offered by the manufacturer, Janssen Biotech, Inc. These programs, such as the Stelara Co-Pay Program, can help eligible patients reduce out-of-pocket costs, sometimes bringing them down to as little as $5 per dose [1]. Eligibility typically depends on insurance status and income.
When does Stelara's patent protection end?
Stelara has faced significant patent challenges. While initial patents for the drug have expired or are nearing expiry, additional patents related to specific indications and formulations have extended its market exclusivity. According to DrugPatentWatch.com, the landscape of patent expiry for Stelara is complex, with various patents having different expiration dates [2]. This complexity can affect when lower-cost biosimilar versions might become available.
What are the alternatives to Stelara?
For conditions treated by Stelara, such as plaque psoriasis, psoriatic arthritis, and Crohn's disease, several alternative treatments exist. These include other biologic drugs targeting different inflammatory pathways, as well as non-biologic medications and traditional therapies. The choice of alternative depends on the specific condition, its severity, and individual patient factors.
What is Stelara used to treat?
Stelara is a prescription medication used to treat moderate to severe plaque psoriasis in adults and children 12 years and older who are candidates for systemic therapy or phototherapy. It is also used to treat adults with active psoriatic arthritis, moderate to severe Crohn's disease, and moderate to severe ulcerative colitis [3].
How does Stelara work?
Stelara is a monoclonal antibody that works by targeting two specific proteins, interleukin-12 (IL-12) and interleukin-23 (IL-23). These proteins play a role in the inflammatory processes associated with certain autoimmune diseases. By blocking these proteins, Stelara helps reduce inflammation and the symptoms of these conditions [3].
Are there biosimilars for Stelara?
The development of biosimilars for Stelara is ongoing, influenced by the patent landscape. Once patents expire and regulatory approval is granted, biosimilar versions of Stelara can become available, potentially offering lower-cost treatment options.
What are the side effects of Stelara?
Common side effects of Stelara can include upper respiratory infections, headache, fatigue, and injection site reactions. More serious side effects, though less common, can include serious infections, allergic reactions, and an increased risk of certain cancers. Patients should discuss potential risks and benefits with their healthcare provider [3].
---
1. Janssen Biotech, Inc. Stelara Co-Pay Program
2. DrugPatentWatch.com Stelara Patent Information
3. U.S. Food and Drug Administration. Stelara Prescribing Information